Published Date:2020-11-05 Original Link:https://www.onenessbio.com/en/news_detail71_1.htm No 1 Date of announcement 2020/11/05 Time of announcement 19:15:48 Subject Oneness submits an IND to TFDA on a phase II clinical trial of FB704A, a mAb developed from its own platform, for treating severe neutrophilic asthma.      To which item it meets paragraph 10 Date of events 2020/11/05 Statement...Read More